Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab +/- Chemotherapy in Older Patients with Advanced Non-Small Cell Lung Cancer
NCT04533451Phase 2Active, not recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Nov 2020
- Primary completion
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Cancer and Leukemia Group B. Started Nov 2020; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04533451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04533451.